An increase in CD4+ and CD8+ infiltrating T cells after treatment was seen in one of the responders but not in the other, and cytokine measurement in tumor supernatant was variable, suggesting the need for a more sensitive assay to characterize the effects of imiquimod on the tumor microenvironment in breast cancer skin metastases. The gene discussed is CD8A; the disease is neoplasm.